Naslov
ANTICOAGULATION THERAPY AND INVASIVE MANAGEMENT OF ACUTE NON-ST ELEVATION CORONARY SYNDROMES: GUIDELINES AND EVERYDAY PRACTICE.

Autori
Hadžibegović, Irzal ; Pvulović, Đeiti ; Vujeva, Božo ; Gabaldo, Krešimir ; Knežević Praveček, Marijana Samardžić, Pejo

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Cardiologia Croatica 2012 ; 7(suppl.1) / - , 2012, 3-4

Skup
9. KONGRES HRVATSKOGA KARDIOLOŠKOG DRUŠTVA s međunarodnim sudjelovanjem

Mjesto i datum
Opatija, Hrvatska, 13.10.2012. - 16.10.2012

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Domaća recenzija

Ključne riječi
Anticoagulation therapy ; acute coronary syndromes

Sažetak
Introduction: Latest 2011 NSTE-ACS management guidelines selected fondaparinux as generally preferred agent due to most favorable risk benefit ratio. In addition, the guidelines gave clear recommendations on how we should select patients for invasive or conservative management. There were no recommendations on preferred anticoagulation treatment regarding the timeliness of invasive procedure. We present our 1-year data on anticoagulation therapies for NSTE-ACS in relation to invasive management selection and treatment outcomes. Patients and methods: Data for 187 patients with NSTE-ACS treated in the the CCU in General hospital Slavonski Brod, Croatia form Jan 2011 to Dec 2011 were analyzed. Treatment options, outcomes and complications among patients treated with different anticoagulation agents were analyzed and compared. Results: In all, 66% of all NSTE-ACS patients were treated invasively. Urgent and early angiography was performed in 44% of invasively treated patients. Generally, 58% and 5% of patients received LMWH and UFH, respectively, whereas fondaparinux was administered in 37% of patients. Median age of patients treated with LMWH was 66, compared to 76 in fondaparinux group. There were significantly more patients treated with LMWH and UFH than with fondaparinux in the invasive strategy group. Number of patients treated conservatively with either fondaparinux or LMWH was almost equal. There were no patients treated conservatively with UFH. In-hospital mortality as well as bleeding rate were low, 2, 6% and 2, 1%, with no differences regarding the selection of anticoagulation therapy. Conclusions: Although the guidelines gave preference to fondaparinux, everyday practice in our hospital showed that LMWH was preferred agent, particularly in younger patients selected for early invasive strategy. It would be interesting to evaluate differences among various hospitals and tailor the guidelines according to local practice and individual patient risk profile.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA